In vivo bioavailability predictions from perfused intestine studies.
作者信息
Soria I, Zimmerman C L
出版信息
Int J Clin Pharmacol Ther. 1996 Feb;34(2):90-1.
PMID:8929754
Abstract
摘要
相似文献
1
In vivo bioavailability predictions from perfused intestine studies.基于灌注肠研究的体内生物利用度预测。
Int J Clin Pharmacol Ther. 1996 Feb;34(2):90-1.
2
Disposition of (-)carbovir in the in situ perfused rat liver and intestinal vasculature preparations.（-）卡波韦在原位灌注大鼠肝脏和肠血管系统制剂中的处置。
Drug Metab Dispos. 1993 Jul-Aug;21(4):724-9.
3
The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats.用于预测人体和大鼠口服剂量吸收分数的肠道通透性方法的验证。
Biopharm Drug Dispos. 1996 Dec;17(9):817-8. doi: 10.1002/(SICI)1099-081X(199612)17:9<817::AID-BDD991>3.0.CO;2-M.
4
Intestinal absorption of (-)-carbovir in the rat.大鼠体内（-）-卡波韦的肠道吸收
Pharm Res. 1994 Feb;11(2):267-71. doi: 10.1023/a:1018911609410.
5
Oral absorption of anti-acquired immune deficiency syndrome nucleoside analogues. 2. Carrier-mediated intestinal transport of stavudine in rat and rabbit preparations.
J Pharm Sci. 1996 May;85(5):478-85. doi: 10.1021/js950363a.
6
The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats.验证肠道通透性方法以预测人和大鼠口服剂量的吸收分数。
Biopharm Drug Dispos. 1995 Jan;16(1):71-5. doi: 10.1002/bdd.2510160107.
7
8
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.为何利用大鼠模型预测人体肠道药物吸收和口服生物利用度具有挑战性？
Pharm Res. 2006 Aug;23(8):1675-86. doi: 10.1007/s11095-006-9041-2.
9
In situ studies of regional absorption of lobucavir and ganciclovir from rabbit intestine and predictions of dose-limited absorption and associated variability in humans.洛布卡韦和更昔洛韦在兔肠道内区域吸收的原位研究以及人体剂量限制性吸收和相关变异性的预测。
J Pharm Sci. 2006 Oct;95(10):2276-92. doi: 10.1002/jps.20716.
10
The pharmacokinetics of (-)-carbovir in rats. Evidence for nonlinear elimination.（-）-卡波韦在大鼠体内的药代动力学。非线性消除的证据。
Drug Metab Dispos. 1990 Nov-Dec;18(6):1078-83.
Zotero 插件